ArticleInternational journal of cancer2023
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk.
Open access · hybridAbstract read
In one paragraph
Article in International journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk.International journal of cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
62 authors at 20 institutions in 11 countries.
Marco DicanioDepartment of Biology, University of Pisa, Pisa, Italy.
Matteo GiaccheriniDepartment of Biology, University of Pisa, Pisa, Italy.ORCID 0000-0002-0363-6632
Alyssa Clay-GilmourDepartment of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Greenville, South Carolina, USA.
Angelica MacaudaGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Juan SainzGenomic Oncology Area, GENYO. Center for Genomics and Oncological Research: Pfizer, University of Granada/Andalusian Regional Government, Granada, Spain.ORCID 0000-0002-9355-2423
Mitchell J MachielaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institues of Health, Bethesda, Maryland, USA.
Malwina Rybicka-RamosDepartment of Hematology Specialist Hospital No. 1, Bytom, Poland.
Aaron D NormanDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Ontario, USA.
Agata TyczyńskaDepartment of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institues of Health, Bethesda, Maryland, USA.
Torben BaringtonDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Shaji K KumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Ontario, USA.
Parveen BhattiCancer Control Research, BC Cancer, Vancouver, Canada.
Wendy CozenDivision of Hematology/Oncology, Department of Medicine, School of Medicine, Susan and Henry Samueli College of Health Sciences, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.
Elizabeth E BrownDepartment of Pathology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Anna SuskaPlasma Cell Dyscrasia Center Department of Hematology Jagiellonian University Faculty of Medicine, Kraków, Poland.
Eva K HaastrupDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Robert Z OrlowskiDepartment of Lymphoma - Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Marek DudzińskiDepartment of Hematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland.
Ramon Garcia-SanzMedina A. Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Marcin KruszewskiDepartment of Hematology, University Hospital No. 2 in Bydgoszcz, Bydgoszcz, Poland.
Joaquin Martinez-LopezHospital 12 de Octubre, Compluntense University, CNIO, CIBERONC, Madrid, Spain.
Katia BeiderHematology Division Chaim Sheba Medical Center, Tel Hashomer, Israel.ORCID 0000-0001-7739-7745
Elżbieta Iskierka-JazdzewskaDepartment of Hematology, Medical University of Lodz, Łódź, Poland.
Matteo PelosiniU.O. Dipartimento di Ematologia, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institues of Health, Bethesda, Maryland, USA.
Małgorzata RaźnyDepartment of Hematology, Rydygier Hospital, Cracow, Poland.
Krzysztof JamroziakDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
S Vincent RajkumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Ontario, USA.
Artur JurczyszynPlasma Cell Dyscrasia Center Department of Hematology Jagiellonian University Faculty of Medicine, Kraków, Poland.
Annette Juul VangstedDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Pilar Garrido ColladoDepartment of Hematology, Virgen de las Nieves University Hospital, Granada, Spain.
Ulla VogelNational Research Center for the Working Environment, Copenhagen, Denmark.
Jonathan N HofmannDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institues of Health, Bethesda, Maryland, USA.
Mario PetriniHematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Aleksandra ButrymDepartment of Cancer Prevention and Therapy, Wroclaw Medical University, Wroclaw, Poland.
Susan L SlagerDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Ontario, USA.
Elad ZivDepartment of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
Edyta SuboczDepartment of Hematology, Military Institute of Medicine, Warsaw, Poland.
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
Niels Frost AndersenDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Grzegorz MazurDepartment of Internal Diseases, Occupational Medicine, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland.
Marzena WatekDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Fabienne LesueurInserm, U900, Institut Curie, PSL Research University, Mines ParisTech, Paris, France.ORCID 0000-0001-7404-4549
Michelle A T HildebrandtDepartment of Lymphoma - Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-6769-6872
Daria ZawirskaDepartment of Hematology, University Hospital in Cracow, Cracow, Poland.
Lene Hyldahl EbbesenDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Herlander MarquesLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal and ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Federica GemignaniDepartment of Biology, University of Pisa, Pisa, Italy.
Charles DumontetINSERM 1052/CNRS 5286/University of Lyon, Lyon, France.
Judit VárkonyiDepartment of Hematology and Internal Medicine, Semmelweis University, Budapest, Hungary.
Gabriele BudaHematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Arnon NaglerHematology Division Chaim Sheba Medical Center, Tel Hashomer, Israel.
Agnieszka Druzd-SitekDepartment of Lymphoproliferative Diseases, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Xifeng WuDepartment of Epidemiology, Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Katalin KadarDepartment of Hematology and Internal Medicine, Semmelweis University, Budapest, Hungary.
Nicola J CampDivision of Hematology and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Norbert GrzaskoDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.
Rosalie G WallerDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Ontario, USA.
Celine VachonDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Ontario, USA.
Federico CanzianGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Daniele CampaDepartment of Biology, University of Pisa, Pisa, Italy.ORCID 0000-0003-3220-9944
University of Pisa · ITRigshospitalet · DKMayo Clinic in Florida · USNational Cancer Institute · USThe University of Texas MD Anderson Cancer Center · USGerman Cancer Research Center · DEInstytut Hematologii i Transfuzjologi · PLJagiellonian University · PLMayo Clinic · USSemmelweis University · HUSheba Medical Center · ILWroclaw Medical University · PLAzienda Usl Toscana Centro · ITCracow University of Technology · PLCracow University of Technology · PLFred Hutch Cancer Center · USGdańsk Medical University · PLHospital Universitario Virgen de las Nieves · ESInserm · FRInstituto de Investigación Biomédica de Salamanca · ES
Funding
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Yi Lin · 2015 to 2026
$25.5MOnset and biomarkers for progression of monoclonal gammopathiesR01CA168762 · NCI · MAYO CLINIC ROCHESTER · PI KUMAR, SHAJI KUNNATHU, RAJKUMAR, S VINCENT · 2012 to 2024
$3.2MNCI NIH HHS P50 CA186781NCI NIH HHS R01 CA168762
Abstract
Pleiotropy, which consists of a single gene or allelic variant affecting multiple unrelated traits, is common across cancers, with evidence for genome-wide significant loci shared across cancer and noncancer traits. This feature is particularly relevant in multiple myeloma (MM) because several susceptibility loci that have been identified to date are pleiotropic. Therefore, the aim of this study was to identify novel pleiotropic variants involved in MM risk using 28 684 independent single nucleotide polymorphisms (SNPs) from GWAS Catalog that reached a significant association (P < 5 × 10
Indexed as
Multiple MyelomaAllelesDNA-Binding ProteinsGenetic Predisposition to DiseaseGenome-Wide Association StudyHSP40 Heat-Shock ProteinsHumansOncogenesPhenotypePolymorphism, Single NucleotideRNA-Binding ProteinsDNA-Binding ProteinsDNAJB4 protein, humanFUBP1 protein, humanHSP40 Heat-Shock ProteinsRNA-Binding Proteinsgenetic susceptibilitymultiple myelomapleiotropypleiotropy scanpolymorphisms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.